Tempest Therapeutics
South San Francisco, California, United States · Biopharma, Biotechnology, Healthcare
Tempest Therapeutics is a development-stage biotechnology company.
Key facts
- Headquarters
- South San Francisco, California, United States
- Employees
- 24
- Industries
- Biopharma, Biotechnology, Healthcare
- Status
- Public (TPST)
- Website
- tempesttx.com
- Company page
Recent activity at Tempest Therapeutics
- : Tempest Therapeutics Signs Master Services Agreement with Factor Bioscience
- : SEC 8-K (1.01): On September 22, 2026, Tempest Therapeutics, Inc. entered into a Master Services Agreement (MSA) with Factor Bioscience Inc. The MSA outlines the terms under which Factor will provide research and development services to Tempest, aimed at supporting Tempest’s ongoing development activities. This agreement is crucial as it relates to Tempest's obligations under a prior License and Collaboration Agreement with Factor Bioscience Limited, effective since August 6, 2025. The strategic partnership enhances Tempest's capabilities in developing its biopharmaceutical products and establishes a framework for future collaborative projects.
- : SEC 8-K (8.01): On September 15, 2026, Tempest Therapeutics, Inc. reconvened its Special Meeting of stockholders, which had been previously adjourned twice since July 27, 2026. The primary purpose of this meeting was to obtain approval for a Certificate of Amendment to the company's Restated Certificate of Incorporation. This amendment seeks to modify specified supermajority voting requirements and allow stockholder action by written consent, potentially simplifying governance and decision-making processes. The details of the amendment are outlined in the proxy statement attached as Exhibit A.
- : SEC 8-K (1.01): On September 14, 2026, Tempest Therapeutics, Inc. entered into an exclusive collaboration, option and license agreement with Heibei Senlang Biotechnology Co., Ltd., a PRC company. Senlang has granted Tempest an exclusive option, which is exercisable within four months, to obtain a worldwide exclusive, royalty-bearing, sublicensable license for Senlang's in vivo CAR-T technology, excluding Greater China. The option requires an exercise fee of approximately $447,000, with additional obligations including a nomination fee for each Selected Licensed Product and annual maintenance fees increasing from $10 million to $14 million over time. This collaboration may significantly enhance Tempest's product offerings in the CAR-T space, broadening their development capabilities globally.
- : SEC 8-K (8.01): On August 17, 2026, Tempest Therapeutics, Inc. held a reconvened special meeting of stockholders to address the approval of a Certificate of Amendment to the Company's Restated Certificate of Incorporation. This amendment aims to modify certain supermajority voting requirements and allow for stockholder actions by written consent. The meeting was originally convened and adjourned on July 27, 2026, highlighting an important decision-making process regarding corporate governance. The details of the amendment were shared in the proxy statement distributed to shareholders, indicating active engagement in corporate structure and shareholder rights.
- : TEMPEST THERAPEUTICS
- : TEMPEST THERAPEUTICS
- : Tempest completes acquisition of CAR-T assets from Factor
- : SEC 8-K (3.02): On November 24, 2025, Tempest Therapeutics, Inc. reported the unregistered sale of Common Warrants and shares of Common Stock. This transaction is being executed under the exemptions provided by Section 4(a)(2) and/or Rule 506 of the Securities Act, indicating that these securities have not been registered and are being sold to accredited investors. The specific financial amounts involved in this issuance were not disclosed, nor were the exact terms of the Common Warrants specified. The strategic implications may involve raising capital for business operations while adhering to regulatory compliance for unregistered securities.
- : Tempest Therapeutics, Inc. to Explore Strategic Alternatives to Advance Clinical Oncology Assets
Tempest Therapeutics funding history
| Date | Round | Amount |
|---|---|---|
| Jun 2026 | Seed | $4.1M |
| Apr 2026 | Seed | $2.0M |
| May 2022 | Venture | $15.0M |
| Feb 2019 | Venture | $48.2M |
Leadership
- Matt Angel, President and CEO
- Stephen Brady, Director
- Michael Raab, Director
- Robert Weisskoff, Director
- Stella Xu, Director
- Thomas Woiwode, Director
- Petpiboon Prasit, Director
- Bradley Bolzon, Director
- Thomas Jr., Executive Officer, Director
- Justin Trojanowski, Corporate Controller
- Nicholas Maestas, Chief Financial Officer
Verified email and direct lines for Tempest Therapeutics’s decision-makers are on Fundz. See plans
Employee benefit plans
Tempest Therapeutics files 1 employee benefit plan with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.
Tempest Therapeutics in the news
- Tempest Announces Development Collaboration with Senlang Biotechnology for TPST-4003, a CD7-Targeted Next-Generation In Vivo CAR-T - GlobeNewswire (Jul 21, 2026)
- Tempest Therapeutics Announces Up to $7.5 Million Private Placement - GlobeNewswire (Sep 11, 2026)
- Tempest to Present at the H.C. Wainwright 28th Annual Global Investment Conference - GlobeNewswire (Sep 08, 2026)
- Tempest Reports Second Quarter 2026 Financial Results and Provides Business Update - GlobeNewswire (Aug 13, 2026)
- Tempest Secures Exclusive Option to License Clinical-Stage CD7-Targeted Lentiviral In Vivo CAR-T Platform - GlobeNewswire (Sep 15, 2026)
- Tempest Therapeutics Announces Warrant Exercise for Approximately $2 Million in Gross Proceeds - GlobeNewswire (May 29, 2026)
- Tempest Appoints Global Finance Leader Nancy Freda-Smith to Board of Directors - GlobeNewswire (Sep 23, 2026)
- Tempest Announces Interim Results from Ongoing REDEEM-1 - GlobeNewswire (Feb 25, 2026)
Companies similar to Tempest Therapeutics
- BioLineRx Ltd · Biopharma, Biotechnology, Healthcare, Health Care, Therapeutics
- Os Therapies · Biopharma, Biotechnology, Healthcare, Health Care, Therapeutics
- Lipella Pharmaceuticals · Biopharma, Biotechnology, Healthcare, Health Care, Therapeutics
- Galmed Pharmaceuticals Ltd · Biopharma, Biotechnology, Healthcare, Health Care, Therapeutics
- AbbVie Inc. · Biopharma, Biotechnology, Healthcare, Health Care, Therapeutics
About Tempest Therapeutics: questions and answers
What does Tempest Therapeutics do?
Tempest Therapeutics is a development-stage biotechnology company.
Where is Tempest Therapeutics headquartered?
Tempest Therapeutics is headquartered in South San Francisco, California, United States.
How many employees does Tempest Therapeutics have?
Tempest Therapeutics has about 24 employees.
Has Tempest Therapeutics raised funding?
Yes. Fundz has recorded 4 funding events for Tempest Therapeutics. The most recent, Seed of $4.1M, was in Jun 2026.
Who leads Tempest Therapeutics?
Matt Angel is a President and CEO at Tempest Therapeutics.
What is the latest news on Tempest Therapeutics?
On Sep 28, 2026, Tempest Therapeutics Signs Master Services Agreement with Factor Bioscience
Is Tempest Therapeutics a public company?
Yes. Tempest Therapeutics is publicly traded under the ticker TPST.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy